Up to 40% of patients with non-small cell lung cancer (NSCLC) develop brain metastases (BM), which are associated with poor outcome (median survival \<5 months) ([@CIT0001]). Treatment options include whole-brain radiotherapy (WBRT) with or without corticosteroids. Modifying the radiation dose or fractionation or combining radiotherapy with radiosensitizers have not substantially improved prognosis ([@CIT0004]). More than half of patients treated with WBRT ultimately die of progressive systemic disease ([@CIT0011]).

Erlotinib, an epidermal growth factor receptor (*EGFR*) pathway inhibitor, is currently approved as first-line treatment for advanced NSCLC patients harboring *EGFR* mutations, and, as maintenance, second-line or third-line treatments following chemotherapy ([@CIT0014]). Pre-clinical data show that erlotinib enhances the inhibitory effect of ionizing radiation in lung cancer, and it crosses the blood-brain barrier, so it could be used to provide sufficient radiosensitizing and therapeutic level in the brain ([@CIT0018]).

To exploit the potential radiosensitizing properties, the direct effect on brain metastases, and systemic activity of erlotinib, we examined the role of erlotinib given concurrently with WBRT, then as maintenance.

Methods {#s1}
=======

Patients {#s2}
--------

Inclusion criteria were: histologically or cytologically confirmed NSCLC and newly diagnosed multiple BM documented by MRI or contrast CT scan, but did not require immediate chemotherapy for symptom control; aged 18--76 years; no previous cranial radiotherapy; at least 28 days since any chemotherapy; Glasgow Coma Score of 14 and greater; Karnofsky performance status of 70 and greater; 3 or fewer sites of extra-cranial metastases; adequate renal and liver function; negative pregnancy test; and age-modified (age cut-off 76 years instead of 66 years) Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) class I and II (class I is KPS ≥ 70, controlled primary tumor, metastases to brain only, and class II is uncontrolled primary tumor, or primary controlled, but metastases to brain and other sites) ([@CIT0023]). Patients with other previous or current malignant disease, solitary brain metastasis suitable for stereotactic radiosurgery or surgical resection, previously treated with any *EGFR* anti-cancer therapy or currently being treated with Cox II inhibitor were excluded.

Patients were randomly assigned to receive erlotinib or placebo after telephoning the trials center. Randomization was stratified using: presence/absence of extra-cranial metastases, number of sites of brain metastases, age-modified RTOG RPA score, and center.

Study Design and Treatment {#s3}
--------------------------

We performed a two-stage randomized, multicenter, phase II double-blind, placebo controlled trial (NCT00554775). Multicenter ethics approvals were obtained, and written informed consent from all patients was obtained.

All patients received standard WBRT administered in 20 Gy in 5 daily fractions, starting within 4 weeks of the baseline CT or MR brain scan. Simulation was mandatory for whole brain irradiation and immobilization was recommended. Treatment was delivered by linear accelerator of energy ranging from 4--8 MV photons.

Erlotinib or matched placebo tablets were taken once daily starting on day 1 of WBRT (continuing through weekends). During WBRT the erlotinib dose was 100mg/day (this dose was chosen because of concerns over possible neurotoxicity when the trial was designed). After completing WBRT the erlotinib dose was increased to the standard 150mg/day, until disease progression with symptomatic deterioration. The dose could be reduced or stopped following grade 3 or 4 adverse events that were not controlled by optimal supportive care.

Steroids were limited to dexamethasone; at least 4mg were prescribed during WBRT and for one week after. If medically feasible, the dose was then reduced according to local policy.

Assessments {#s4}
-----------

Within 4 weeks before starting treatment, patients had a physical examination, full blood count, serum chemistry, chest X-ray, CT or MRI scan of the brain, and CT scan of the body. A clinical examination, the mini mental state examination (MMSE), and assessment of motor strength, visual acuity and gait (MVG) were completed before random assignment, two weekly for the first 8 weeks, then monthly until 12 months, and then two-monthly until death. Biological marker assessments, consisting of blood samples and diagnostic tissue (where available), were collected before random assignment. Quality of life (QoL) assessments, using the EuroQol EQ- 5D questionnaire, were made before random assignment, monthly for the first 12 months, and then at 18 and 24 months after random assignment. Adverse events were recorded up to 28 days after finishing erlotinib treatment, and graded using the National Cancer Institute Common Terminology Criteria of Adverse Events (version 3).

Translational Research {#s5}
----------------------

Sufficient diagnostic biopsy material (paraffin blocks) and DNA were available for 35 patients of 36 who provided blocks. The DNA extraction was performed using Qiagen FFPE DNA Extraction Kit. *EGFR* analysis was performed using Qiagen *EGFR* RGQ polymerase chain reaction (PCR) Kit for real-time PCR analysis of 29 somatic mutations in the *EGFR* gene (Qiagen, Hilden, Germany).

Statistical Analysis {#s6}
--------------------

The primary endpoint was 2-month neurological progression-free survival (nPFS), defined as evidence of either clinical or radiological progression, ie, any one of the following: a loss of 3 points on the MMSE questionnaire compared to baseline; a loss of 3 points on the central nervous system (CNS) scale for MVG or a loss of 2 points for VG (ie, visual acuity & gait assessed by telephone) when compared to baseline; a deterioration of 10 or more points in Karnofsky performance status, compared to baseline, at the 6 week assessment or later; an increase in dexamethasone dose suggestive of progressive disease at the 6 week assessment or later; an increase of 20% or greater in the sum of the longest diameters (LDs) of all metastases present at a baseline of 0.5cm or greater, taking as reference the smallest sum LD recorded since the start of treatment; or the appearance of a new metastasis. Other end points included overall survival (OS), adverse events, and QoL.

A Simon minimax two-stage design for phase II studies was used, to detect a neurological PFS rate at 2 months of 65% or greater with erlotinib, assuming that neurological PFS is less than 50% among patients treated with WBRT only. Using a one-sided 10% statistical significance level and 90% power, the target accrual was 40 patients in the erlotinib arm in the first stage. If, after 2 months, 20 or more patients were alive and neurological progression-free the trial would continue to the second phase and recruit an additional 32 patients for each arm. The same number of placebo patients was specified (ie, a total target of 80 patients in the first stage). The data was reviewed at the end of the first stage by an independent data monitoring committee (IDMC) and all analyses were performed on an intention-to-treat basis. Hazard ratios (HRs), with 95% confidence intervals (CIs) and two-sided *P* values, were calculated using the Cox proportional hazards model. Survival curves are presented using the Kaplan-Meier method. Patients were censored using the date they were last seen if no event had occurred. Analysis was performed on an intention-to-treat (ITT) basis and generated using SAS software version 9.3 (SAS Institute, Cary, NC).

Results {#s7}
=======

Eighty patients were recruited (June 2009 to June 2010) from 18 centers across the UK National Cancer Research Network: 40 placebo and 40 erlotinib. [Table 1](#T1){ref-type="table"} shows the baseline characteristics, and [Figure 1](#F1){ref-type="fig"} the CONSORT diagram.

###### 

Baseline characteristics

  Variable                      WBRT+placebo (n = 40)\*   WBRT+erlotinib (n = 40)†
  ----------------------------- ------------------------- --------------------------
  Age at random assignment, y                             
   Median                       62.2                      61.3
   Range                        41 - 73                   48 - 75
  Sex                                                     
   Female                       19 (47.5)                 25 (62.5)
   Male                         21 (52.5)                 15 (37.5)
  Age-modified RTOG RPA‡                                  
   I                            8 (20.0)                  10 (25.0)
   II                           32 (80.0)                 30 (75.0)
  Brain metastases, no.                                   
   ≤3                           26 (65.0)                 23 (57.5)
   \>3                          14 (35.0)                 17 (42.5)
  Extra-cranial metastases                                
   Absent                       16 (40.0)                 15 (37.5)
   Present                      24 (60.0)                 25 (62.5)
  Karnofsky performance score                             
   70                           13 (32.5)                 9 (22.5)
   80                           15 (37.5)                 22 (55.0)
   90                           9 (22.5)                  9 (22.5)
   100                          3 (7.5)                   0 (0.0)
  Histology                                               
   Adenocarcinoma               20 (50.0)                 23 (57.5)
   Squamous                     7 (17.5)                  5 (12.5)
   Other                        6 (15.0)                  5 (12.5)
   Unspecified                  7 (17.5)                  7 (17.5)

\* One patient died before treatment, and one patient progressed before treatment.

† Three patients died before treatment.

‡ Radiation Therapy Oncology Group Recursive Partitioning Analysis.

![CONSORT diagram, including the number of patients who started and continued trial treatment, and the reasons for stopping early.](jnci.j_dju151_f0001){#F1}

Treatment Compliance {#s8}
--------------------

Seventy-five patients (94%) started trial treatment (n = 5 had either died or progressed beforehand). Median time on the study drug was 1.3 (placebo) and 1.8 (erlotinib) months. Thirty-one patients in each group (78%) took their erlotinib/placebo tablets for at least 75% of the time they were in the trial, ie, until they died/stopped treatment early (Supplementary [Table 1](#T1){ref-type="table"}, available online). Two patients in the placebo arm and 3 in the erlotinib arm temporarily stopped the study drug at 7 or later days. Only one patient in the erlotinib arm experienced toxicity leading to a dose reduction from 150 to 100mg daily (due to skin rash).

One patient (erlotinib) did not receive any WBRT. Six patients (placebo) and 5 patients (erlotinib) did not receive WBRT for 5 consecutive days excluding weekends ([Figure 1](#F1){ref-type="fig"}).

Efficacy {#s9}
--------

Fifteen patients (37.5%) in each treatment group were alive and free from neurological progression at 2 months, less than the target of 20 or greater, so the IDMC recommended not proceeding to stage 2.

The median follow up was 12.6 months (censoring those who had died). There were 35 placebo and 38 erlotinib patients who had died or had neurological progression, with median neurological PFS of 1.6 months in each group ([Figure 2](#F2){ref-type="fig"}). The 2-month PFS rate was 38.9%, 95% CI = 23.6% to 54.2% (erlotinib), compared to 38.5%, 95% CI = 23.2% to 53.7% (placebo).

###### 

**A)** Neurological progression-free survival (NPFS) and **B)** overall survival (OS) curves according to treatment arms in all patients. The number of patients at risk in each group at various time points is located under each graph.
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The unadjusted HR for neurological PFS was 0.99 (95% CI = 0.62 to1.58; *P* = .97), which became 0.95 (95% CI = 0.59 to 1.54; *P* = .84) after allowing for the randomization stratification factors. The adjusted HR among the 75 patients who started the study drug was 0.89 (95% CI = 0.54 to 1.46; *P* = .65).

Sixty-six patients died (31 placebo and 35 erlotinib), with a median OS of 2.9 and 3.4 months, respectively ([Figure 2](#F2){ref-type="fig"}). The unadjusted OS HR was 0.94 (95% CI = 0.58 to 1.54; *P* = .81), and 0.95 (95% CI = 0.58 to 1.55; *P* = .83) after allowing for stratification factors. The adjusted HR among the 75 patients who started the study drug was 0.90 (95% CI = 0.54 to1.51; *P* = .69). The 6-month OS rates for RTOG RPA class I patients were: 56.3% (placebo arm, n = 8 and 3 deaths); and 45.0% (erlotinib arm, n = 10 and 8 deaths). For RTOG class II patients, the rates were: 24.3% (placebo n = 32 and 28 deaths); and 16.6% (erlotinib, n = 30 and 27 deaths) ([Supplementary Figure 1](http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/dju151/-/DC1), available online).

Toxicity {#s10}
--------

Twenty-eight (70.0%) patients suffered a grade 3 or 4 adverse event in each treatment group ([Table 2](#T2){ref-type="table"}). More patients in the erlotinib group experienced rash as expected (20.0% vs 5.0%); and fewer erlotinib patients had grade 3/4 fatigue (17.5% vs 35.0%). No suspected unexpected serious adverse reactions were reported.

###### 

Reported grade 3 or 4 toxicities

  Variable                                   WBRT+placebo (n = 40)\*   WBRT+erlotinib (n = 40)†
  ------------------------------------------ ------------------------- --------------------------
  Any toxicity (each patient counted once)   28 (70.0)                 28 (70.0)
   Dyspnoea                                  15 (37.5)                 14 (35.0)
   Fatigue                                   14 (35.0)                 7 (17.5)
   Rash                                      2 (5.0)                   8 (20.0)
   Infection                                 2 (5.0)                   5 (12.5)
   Myopathy                                  4 (10.0)                  2 (5.0)
   Anorexia                                  3 (7.5)                   2 (5.0)
   Pain                                      3 (7.5)                   2 (5.0)
   Diarrhoea                                 2 (5.0)                   2 (5.0)
   Headache                                  4 (10.0)                  0 (0.0)
   Muscle weakness (myopathy)                3 (7.5)                   0 (0.0)
   Anaemia                                   2 (5.0)                   0 (0.0)
   Dehydration                               0 (0.0)                   2 (5.0)
   Pulmonary embolism                        1 (2.5)                   1 (2.5)
   Seizure                                   2 (5.0)                   0 (0.0)
   Somnolence                                1 (2.5)                   1 (2.5)
   Constipation                              0 (0.0)                   1 (2.5)
   Dry skin                                  0 (0.0)                   1 (2.5)
   Nausea                                    0 (0.0)                   1 (2.5)
   Pneumonitis                               1 (2.5)                   0 (0.0)
   Other                                     9‡ (22.5)                 10║ (25.0)

\* One patient died before treatment, and one patient progressed before treatment.

† Three patients died before treatment.

‡ Ataxia, facial oedema, fainted, fractured humerus, hydrocephalus, low haemoglobin, neuropathy-motor, pleural effusion, urinary retention.

║ Alopecia, aspiration, dysasthria, dyspepsia, expressive dysphasia, hyperglycemia, hypotension, metabolic acidosis, pancreatitis, raised alanine transaminase.

Quality of Life {#s11}
---------------

There was no evidence of differences in the QoL scores between treatment groups at one or two months, adjusting for baseline scores (all *P* ≥ .40) ([Supplementary Table 2](http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/dju151/-/DC1), available online).

Biological Substudy {#s12}
-------------------

The activating *EGFR* mutation-positive rate was only 2.9% (1/35). This patient had a neurological PFS time of 1.3 months and survived 1.6 months after random assignment.

Discussion {#s13}
==========

We showed that concurrent erlotinib with WBRT followed by maintenance erlotinib did not improve neurological PFS or OS in our patients with multiple brain metastases. The median neurological PFS and OS in this group were disappointingly low; 1.6 months and 3.4 months respectively, despite selecting only patients with age-modified RTOG RPA class I and II.

However, a recent single arm phase II trial (40 patients) of erlotinib plus concurrent WBRT reported a median survival of 11.8 months and a high intracranial response rate, but more than 50% of patients had activating *EGFR* mutations. Similar to our study, they found erlotinib with WBRT was well tolerated with no unexpected neurotoxicity ([@CIT0024]). In another phase II study, 28 NSCLC patients harboring *EGFR* mutations were treated with either gefitinib or erlotinib alone ([@CIT0025]). Response rates in the brain were high, with 23 patients (83%) achieving a partial response, with a median progression-free survival of 6.6 months, and an OS of 15.9 months. Both studies showed encouraging results with *EGFR* tyrosine-kinase inhibitors (TKIs) with or without WBRT in patients with activating *EGFR* mutation tumors in contrast to our study where patients had predominantly wild-type *EGFR* tumors. There have been several case reports describing disease response in the brain metastases harboring *EGFR* mutations with TKI alone, and also that refractory CNS and lepto-meningeal metastases can be improved by escalating the dose of erlotinib, correlated with higher cerebrospinal fluid (CSF) concentrations ([@CIT0019], [@CIT0026], [@CIT0027]).

In contrast to Welsh et al ([@CIT0024]), we found the frequency of *EGFR* mutations in our treated patients was low (3%). This low frequency mutation rate was similar to that reported in another recent study examining the frequency of *EGFR* mutations in brain metastases among NSCLC patients ([@CIT0028]). In 77 brain tumor samples, the rate of *EGFR* mutations was 3.9% (3/77) in contrast to a *KRAS* mutation rate of 39% (30/77). The lack of anti-brain metastasis activity in *EGFR* wild-type tumors is compatible with a reported retrospective study. This study of 69 NSCLC patients with brain metastases found responses were only observed in patients with activating *EGFR* mutation (82%) but not wild-type tumors ([@CIT0022]). Additionally, median time to progression within the brain and OS were 5.8 and 3.1 months for unselected patients, compared to 11.7 and 12.9 months, respectively, for patients harboring *EGFR* mutations. We hypothesize that for *EGFR* wild-type tumors, erlotinib concentration achieved in the CSF is sub-therapeutic and also too low to exert radio-sensitizing activity. Further research could explore escalating the erlotinib dose before WBRT or strategies to disrupt the blood-brain barrier in order to increase erlotinib CSF penetration.

We also found that overall median survival for unselected patients with multiple brain metastases treated with WBRT alone was low (2.9 months) despite selecting only patients with Karnofsky performance statuses of 70 and greater ([@CIT0023]). Welsh et al ([@CIT0024]) used 3000cGy WBRT in 10 fractions, and we used 2000cGy WBRT in five fractions, but this is unlikely to be the main reason why our patients had a poor survival. Previous trials and a systematic review reported no improvement in the frequency and duration of response, survival or QoL for radiation doses ranging from 20 Gy in five fractions to 50 Gy in 20 fractions ([@CIT0005], [@CIT0029], [@CIT0030]). The RTOG report that patients had a median survival of 7.1, 4.2 and 2.3 months for classes I, II and III, respectively. The sole criterion required to classify a patient in the poorest prognostic group (class III) is a KPS of less than 70. Despite excluding patients with KPS of less than 70, the median OS in our trial was similar to that reported for RPA class III. The three-tier RTOG RPA prognostic classification, based on several cancers (lung, breast, melanoma, colorectal, and others), may not be entirely applicable to NSCLC patients with multiple brain metastases.

Our finding does not preclude the possibility that erlotinib is effective for *EGFR* mutation positive tumors as only 2.9% of assessed patients manifested *EGFR* mutations. Future studies should focus on the role of erlotinib with or without WBRT in NSCLC patients harboring *EGFR* mutations. This includes comparing erlotinib alone with WBRT plus erlotinib, erlotinib alone with stereotactic radiotherapy or surgery for patients with 3 or fewer brain metastases, escalating the dose of erlotinib in patients with CNS relapse after TKI treatment, or strategies to disrupt blood brain barrier in order to increase erlotinib delivery to the brain.

In conclusion, we showed no statistically significant improvement in neurological PFS or OS in unselected patients treated with concurrent erlotinib and WBRT followed by maintenance erlotinib compared to placebo.
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